title: [Treatment of oropharyngeal and esophageal mycoses in immunodeficient patients with fluconazole (Diflucan, Pfizer)].
abstract: Thirteen patients with oropharyngeal and oesophageal mycosis were treated with a new triazole antimycotic, fluconazole. In the whole group in addition to the basic neoplastic disease as multifactorial predisposition to mycotic infection was revealed. After treatment a 100% clinical as well a laboratory effect was achieved. However, within one month a relapse developed in three of eight patients and reinfection in four of eight (renewal of laboratory evidence). The preparation was well tolerated by the patients, no laboratory signs of organ toxicity were revealed. In patients with cumulation of predisposing factors for mycotic infection the authors recommend long-term prophylactic protection with a small dose of fluconazole.
authors.affiliation: II. interní klinika 1. LF UK, Praha.
authors.forename: J
authors.initials: J
authors.lastname: Háber
authors.forename: E
authors.initials: E
authors.lastname: Kolesková
authors.forename: A
authors.initials: A
authors.lastname: Kostelková
authors.forename: P
authors.initials: P
authors.lastname: Klener
authors.forename: A
authors.initials: A
authors.lastname: Slavícek
authors.forename: A
authors.initials: A
authors.lastname: Palecek
authors.forename: I
authors.initials: I
authors.lastname: Másová
mesh_terms: D000328:Adult; D000368:Aged; D004935:Esophageal Diseases / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000276:immunology; D009960:Oropharynx; D010608:Pharyngeal Diseases / Q000188:drug therapy* / Q000276:immunology; D010865:Pilot Projects
chemical_list: D015725:Fluconazole
vernacular_title: Lécba orofaryngeální a jícnové mykózy u imunodeficitních nemocných Fluconazolem (Diflucan, Pfizer).